Other Mutations: HLA+

NCT05389514: Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

NCT05389514
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS, HLA+
Breast Cancer Tissue: 
Recruitment Status: Available

Drug Category: Chemotherapy, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have cancer that expresses the KRAS G12V mutation & appropriate HLA class II match (HLA-DRB1*07:01)
Exclusions: 
https://ClinicalTrials.gov/show/NCT05389514

NCT05129280: A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

NCT05129280
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MAGE-A1/3/4/6, HLA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express HLA-A*02:01 AND MAGE-A4
Exclusions: Patients with a history or clinical evidence of central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT05129280

Up ↑